Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

Investigational New Drugs

Volumn 31, Issue 1, 2013, Pages 175-182

  Manegold, Christian ^a,j   Vansteenkiste, Johan ^b   Cardenal, Felipe ^c   Schuette, Wolfgang ^d   Woll, Penella J ^e   Ulsperger, Ernst ^f   Kerber, Anne ^g   Eckmayr, Josef ^h   Von Pawel, Joachim ⁱ  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d Hospital Martha Maria Halle Dölau   (Germany)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f KHR Hietzing   (Austria)

^g MERCK KGAA   (Germany)

^h Klinikum Kreuzschwestern Wels   (Austria)

ⁱ ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^j UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

Cilengitide; Docetaxel; Integrin inhibitor; Non small cell lung cancer; Second line treatment

Indexed keywords

ALPHAVBETA5 INTEGRIN; CILENGITIDE; DOCETAXEL; VITRONECTIN RECEPTOR;

ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; CANCER PAIN; CANCER RADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS; SURVIVAL RATE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTEGRINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SNAKE VENOMS; TAXOIDS;

EID: 84873077884     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9842-6     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Yang P, Allen MS, Aubry MC et al (2005) Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 128:452-462
3. Felip E, Gridelli C, Baas P et al (2011) Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 22:1507-1519
4. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103
5. Dancey J, Shepherd FA, Gralla RJ, Kim YS (2004) Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 43:183-194
6. Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362
7. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597
8. Pallis AG, Agelaki S, Agelidou A et al (2010) A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. BMC Cancer 10:633
9. Arnaout MA, Goodman SL, Xiong JP (2007) Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol 19:495-507
10. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22
11. Stevens MM, George JH (2005) Exploring and engineering the cell surface interface. Science 310:1135-1138
12. Tucker GC (2006) Integrins: molecular targets in cancer therapy. Curr Oncol Rep 8:96-103
13. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B (2006) Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 65:1536-1543
14. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500-1502
15. Germer M, Kanse SM, Kirkegaard T et al (1998) Kinetic analysis of integrin-dependent cell adhesion on vitronectin - the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur J Biochem 253:669-674
16. Loges S, Butzal M, Otten J et al (2007) Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochem Biophys Res Commun 357:1016-1020
17. Manegold C, Vansteenkiste J, Cardenal J et al (2009) Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with stage IV non-small cell lung cancer. J Clin Oncol 27: Abstract 8014
18. Dingemans AM, van den Boogaart V, Vosse BA, van Suylen RJ, Griffioen AW, Thijssen VL (2010) Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer 9:152
19. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
20. Sipos B, Henopp T, Kalthoff H et al (2010) Expression of functional forms of vβ3 and vβ5 integrins, laminin-5 and vitronectin in common human tumors: Consequences for cilengitide targeting. Cancer Res 8: Abstract 2321
21. Suzuki S, Takahashi T, Nakamura S et al (1993) Alterations of integrin expression in human lung cancer. Jpn J Cancer Res 84:168-174
22. Nabors LB, Mikkelsen T, Rosenfeld SS et al (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651-1657
23. Reardon DA, Fink KL, Mikkelsen T et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610-5617
24. Di Maio M, Perrone F, Chiodini P et al (2007) Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 25:1377-1382
25. Cufer T, Vrdoljak E, Gaafar R et al (2006) Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 17:401-409
26. Leong SS, Toh CK, Lim WT et al (2007) A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol 2:230-236
27. Uygun K, Aksu G, Cicin I et al (2008) The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma. Med Oncol 25:408-414
28. Nabors LB, Mikkelsen T, Rosenfeld SS et al (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651-1657
29. Vansteenkiste J, Brummendorf T, Schuette W et al (2010) Safety of different regimens of the novel integrin inhibitor cilengitide combined with cetuximab and platinum-based chemotherapies. J Clin Oncol 28: Abstract e18067